Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06811246 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT06811246 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 20 participants.
The verdict
NCT06811246, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The goal of this study is to learn what happens to the medication islatravir (ISL), in a healthy person's body over time--called a pharmacokinetic (PK) study. Researchers want to compare the amount of islatravir in the blood when it is taken alone as a single dose and when it is taken with multiple doses of another medication called lamivudine (3TC).
Interventions
- DRUG Lamivudine (3TC)
- DRUG Islatravir (ISL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-02-07 |
| Est. Completion | 2024-07-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06811246
The ClinicalTrials.gov registry entry for NCT06811246 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lamivudine (3TC) is the first listed.
NCT06811246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06811246 about?
NCT06811246 is a clinical study titled "A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)". The goal of this study is to learn what happens to the medication islatravir (ISL), in a healthy person's body over time--called a pharmacokinetic (PK) study. Researchers want to compare the amount of islatravir in the blood when it is taken alone as a single dose and when it is taken with multiple ...
What is the current status of trial NCT06811246?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-02-07. Estimated completion is 2024-07-14.
What interventions are being tested in trial NCT06811246?
The interventions under investigation include: Lamivudine (3TC) (DRUG), Islatravir (ISL) (DRUG).
Who is sponsoring clinical trial NCT06811246?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.